Current Report Filing (8-k)
June 02 2022 - 4:06PM
Edgar (US Regulatory)
0001500198
false
0001500198
2022-05-31
2022-05-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 31, 2022
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40439 |
|
27-0863354 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
7599 Anagram Dr., Eden Prairie, MN 55344
(Address of principal executive offices and zip
code)
952-426-1383
(Registrant’s telephone number including area code)
(Registrant’s former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
NMTC |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security
Holders.
At the annual meeting (the
“Annual Meeting”) of stockholders of NeuroOne Medical Technologies Corporation (the “Company”) on May 31, 2022,
stockholders (i) elected one Class II director to the Company’s Board of Directors to serve a three-year term until the 2025
annual meeting of stockholders, and (ii) ratified the appointment of Baker Tilly U.S., LLP as the Company’s independent registered
public accounting firm for the fiscal year ending September 30, 2022. Proposals are described in detail in the Company’s definitive
proxy statement filed with the Securities and Exchange Commission on April 29, 2022.
A total of 9,491,751 shares
of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 58.62% of the shares
of common stock outstanding as of the record date for the Annual Meeting.
The results of the voting are shown below:
Proposal 1—Election of Director
| Class I Nominee | |
Votes For | |
Votes Withheld | |
Broker Non-Votes |
| David Rosa | |
4,552,178 | |
411,044 | |
4,528,529 |
Proposal 2—Ratification of Appointment of Independent Registered
Public Accounting Firm
| Votes For | |
Votes Against | |
Votes Abstain |
| 9,421,086 | |
44,729 | |
25,936 |
Item
8.01 Other Events.
On June 2, 2022, NeuroOne Medical Technologies
Corporation issued a press release providing a copy of the Annual Letter to Shareholders. A copy of this press release is filed herewith
as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
NEUROONE MEDICAL TECHNOLOGIES CORPORATION |
| Dated: June 2, 2022 |
|
|
| |
By: |
/s/ David Rosa |
| |
|
David Rosa |
| |
|
Chief Executive Officer |
2
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Apr 2023 to Apr 2024
